- The FDA has accepted for review BeyondSpring Inc’s (NASDAQ:BYSI) marketing application seeking approval for the use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
- Under the priority review, the target action date is set for November 30.
- Plinabulin acts as a selective immunomodulating microtubule-binding agent (SIMBA), with immune anti-cancer activities and broad activities to prevent CIN across chemotherapy and cancer types.
- Price Action: BYSI shares are up 11.4% at $11.55 during the market session on the last check Tuesday.
Jonathan Gear Names CEO of Clarivate
Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear has assumed the role of Chief Executive Officer with the retirement of Jerre Stead from that role
